SCHEMBL6754398

SCHEMBL6754398

NC(=O)c1cncc(-c2cncc(C(N)=O)c2)c1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 9/20 0.67
MKNK2 Q9HBH9 9/20 0.67
CYP11B2 P19099 3/20 0.58
CYP11B1 P15538 1/20 0.58
MAP4K4 O95819 3/20 0.56
CHEK2 O96017 1/20 0.50
DGAT1 O75907 1/20 0.50
SIRT2 Q8IXJ6 3/20 0.48
SIRT1 Q96EB6 3/20 0.48
SIRT3 Q9NTG7 3/20 0.48
F7 P08709 1/20 0.48
F3 P13726 1/20 0.48
SARM1 Q6SZW1 1/20 0.48
SIRT6 Q8N6T7 1/20 0.48
SIRT5 Q9NXA8 1/20 0.48
SIRT4 Q9Y6E7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2488476 0.88 MKNK1 (0.77) MKNK1MKNK2CYP11B2CYP11B1MAP4K4
SCHEMBL30108186 0.88 MKNK1 (0.65) MKNK1MKNK2CYP11B2CYP11B1MAP4K4
SCHEMBL2841794 0.87 SIRT2 (0.54) MKNK1MKNK2CYP11B2CYP11B1MAP4K4
SCHEMBL1785559 0.87 MKNK1 (0.68) MKNK1MKNK2CYP11B2CYP11B1MAP4K4
SCHEMBL28760070 0.87 MKNK1 (0.57) MKNK1MKNK2CYP11B2CYP11B1MAP4K4
SCHEMBL31242967 0.87 CYP11B2 (0.55) MKNK1MKNK2CYP11B2CYP11B1MAP4K4
SCHEMBL27987797 0.87 CYP11B2 (0.55) MKNK1MKNK2CYP11B2CYP11B1MAP4K4
SCHEMBL13188346 0.85 MKNK1 (0.77) MKNK1MKNK2CYP11B2CYP11B1CHEK2
SCHEMBL30108236 0.85 MKNK1 (0.77) MKNK1MKNK2CYP11B2CYP11B1CHEK2
SCHEMBL12647206 0.85 MKNK1 (0.69) MKNK1MKNK2CYP11B2CYP11B1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 MKNK1 2259/4885MKNK2 1676/4885CYP11B2 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.